Reason for request
Re-assessment of the actual benefit (AB) and the level of improvement in actual benefit (IAB) at the request of the applicant.
Clinical Benefit
| Low |
The actual benefit of MYOZYME remains low in the treatment of late-onset Pompe disease. |
Clinical Added Value
| minor |
The improvement in actual benefit remains minor (level IV) in the treatment of late-onset Pompe disease. |
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
YBuYtzj7ZuPMv0NR
Listen
